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Abstract Secretomotor reflexes in the gastrointestinal (GI)
tract are important in the lubrication and movement of
digested products, absorption of nutrients, or the diarrhea
that occurs in diseases to flush out unwanted microbes.
Mechanical or chemical stimulation of mucosal sensory
enterochromaffin (EC) cells triggers release of serotonin
(5-HT) (among other mediators) and initiates local reflexes
by activating intrinsic primary afferent neurons of the
submucous plexus. Signals are conveyed to interneurons or
secretomotor neurons to stimulate chloride and fluid
secretion. Inputs from myenteric neurons modulate secre-
tory rates and reflexes, and special neural circuits exist to
coordinate secretion with motility. Cellular components of
secretomotor reflexes variably express purinergic receptors
for adenosine (A1, A2a, A2b, or A3 receptors) or the
nucleotides adenosine 5′-triphosphate (ATP), adenosine
diphosphate (ADP), uridine 5′-triphosphate (UTP), or
uridine diphosphate (UDP) (P2X1-7, P2Y2, P2Y4, P2Y6,
P2Y12 receptors). This review focuses on the emerging
concepts in our understanding of purinergic regulation at
these receptors, and in particular of mechanosensory
reflexes. Purinergic inhibitory (A1, A3, P2Y12) or excitatory
(A2, P2Y1) receptors modulate mechanosensitive 5-HT
release. Excitatory (P2Y1, other P2Y, P2X) or inhibitory
(A1, A3) receptors are involved in mechanically evoked
secretory reflexes or “neurogenic diarrhea.” Distinct neural
(pre- or postsynaptic) and non-neural distribution profiles
of P2X2, P2X3, P2X5, P2Y1, P2Y2, P2Y4, P2Y6, or P2Y12
receptors, and for some their effects on neurotransmission,
suggests their role in GI secretomotor function. Luminal
A2b, P2Y2, P2Y4, and P2Y6 receptors are involved in fluid
and Cl-, HCO3
-, K+, or mucin secretion. Abnormal receptor
expression in GI diseases may be of clinical relevance.
Adenosine A2a or A3 receptors are emerging as therapeutic
targets in inflammatory bowel diseases (IBD) and gastro-
protection; they can also prevent purinergic receptor
abnormalities and diarrhea. Purines are emerging as
fundamental regulators of enteric secretomotor reflexes in
health and disease.
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Introduction
Gastrointestinal (GI) secretions in coordination with motil-
ity are important in digestion of food particles, lubrication,
nutrient absorption, regulation of pH and solute concentra-
tion, and elimination of waste products. Diarrhea occurs in
GI diseases to flush out noxious chemicals or unwanted
microbes. Intestinal chloride secretion provides a driving
force for fluid movement and obligate transport of water
into the lumen. Under normal circumstances, mucosal
chloride secretion is very low, but can reach extraordinary
rates when challenged by enterotoxins or various secreto-
gogues. Hallmarks of enteric infections or inflammatory
bowel diseases (IBD) are malaise and diarrhea; the other
extreme is constipation that occurs in patients with
idiopathic constipation, constipation-predominant irritable
bowel syndrome (IBS), or opioid-induced constipation.
Structural or functional changes in the enteric nervous
system (ENS), in neurotransmitters, signaling pathways, or
other components of enteric neural reflexes may be the
basis for the pathogenesis of disturbances in gut motor
function.
The current review will focus primarily on the role of
purines in secretomotor function in the GI system. The
enterochromaffin–neural circuit–epithelial reflex pathway is
our target for understanding secretomotor function in the
intestinal tract. All cellular components of mucosal reflexes
express purinergic receptors, and this review will focus on
these receptors, their distribution, and function in mucosal
reflexes and secretomotor function in the GI tract. The
enteric neural circuits and cellular components involved in
neurosecretory reflexes will first be briefly reviewed. A
brief overview and basic knowledge of purinoceptor
classification, pharmacology, receptor ligands and their
selectivity is necessary in order to understand the concepts
forwarded in this review. Emerging concepts will be
reviewed in our understanding of purinergic regulation in
mucosal reflexes, with particular emphasis on enterochro-
maffin cells (EC), mucosal reflexes, receptor distribution,
and luminal P2 receptors involved in epithelial ion transport
and fluid secretion. In addition, we review recent findings
on purinergic regulation of gastric secretions, and in
relation to gastric mucosal protection. Our review would
not be complete without a very brief description of the
emerging role of purinergic receptors as therapeutic targets
in IBD [2] or implications of purine receptor abnormalities
(up- or downregulation) in GI diarrhea diseases. The reader
is also referred to more general reviews on purinergic
signaling [12], GI secretomotor function and dysfunction
[25, 26], epithelial secretion, and hepatobiliary function
[92]. Other relevant reviews include adenosine neuro-
modulation [20], purines in mechanosensory signaling
[26], ATP as a sensory transmitter [6], and P2Y1 receptors
in secretomotor function [113], or P2X receptors as
potential targets in IBS [40].
Enterochromaffin–neural–epithelial reflex pathways
The secretory reflex is composed of sensory EC cells,
intrinsic primary afferent neurons (IPANs), various inter-
neurons, secretomotor neurons, interplexus neurons for
coordinating secretion and motility or for secretomotor
function [11], and the epithelial cells involved in ion
transport and fluid secretion in the gut lumen (Fig. 1).
Luminal stimulation by nutrients, changes in pH, mechan-
ical forces, changes in solute concentration, luminal
irritants, or invading enteropathogenic microorganisms will
activate the EC cells to secrete serotonin (5-HT) among
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other mediators to trigger secretomotor reflexes leading to
chloride, bicarbonate, potassium, mucin, and fluid secre-
tion. EC cells communicate with both submucosal and
myenteric IPANS to initiate secretomotor reflexes. Mucosal
stimulation and activation of secretomotor reflexes via long
myenteric pathways may play a role in the coordination of
intestinal motility, secretion, and blood flow [88]. This
review is restricted to submucous pathways and secreto-
motor reflexes. Under physiological circumstances, large
fluctuations in secretions can occur depending on the
stimulus. Crohn’s disease or Clostridium difficile toxin A
(TxA) can cause diarrhea and alterations in secretion.
However, the diarrhea observed in IBD is mainly mal-
absorptive not secretory; in the inflamed gut, secretion
actually decreases. Hypersecretion due to infection is
helpful in flushing to rid the lumen of a pathogen.
Release of sensory mediators from EC cells activates the
afferent nerve endings of IPANs to trigger a secretory
reflex. IPANs detect sensory information from the luminal
environment in the form of action potentials carried in their
primary afferent process. The sensory information is
decoded and integrated in the cell soma and then relayed
to interneurons or secretomotor neurons to elicit a secretory
reflex. These IPANs in submucous ganglia have AH cell
electrophysiological characteristics and comprise 15% of
submucous neurons (and 25-30% of myenteric neurons).
The axonal processes of submucous IPANs are known to
project to other IPANs and to submucous or myenteric
neurons. They have Dogiel type II morphology and project
in all directions in the submucous plexus [25].
One type of IPAN in the submucous plexus has one
sensory process projecting to the mucosa and responds to
mucosal distortion/deformation at sites less than 1 mm2
from the recording site. Another type of IPAN in the
submucous plexus is sensitive to distention [26, 38, 112].
Notable differences exist in the chemical coding of these
neurons in human, porcine, and rodent intestine [25]. After
activation of IPANs, release of transmitters at synapses with
interneurons or secretomotor neurons leads to epithelial
secretion. 5-HT interplexus neurons send a process to
synapse with secretomotor neurons expressing 5-HT3


































































Fig. 1 Generic intestinal secretory reflex based on guinea pig
intestine. Neural reflex pathway regulating secretion includes EC
sensory cells that release 5-HT to activate IPANS projecting to the
mucosa, to submucous ganglia, and to myenteric ganglia. IPANS
synapse with several types of cholinergic (CHAT) and vasoactive
intestinal peptide (VIP) secretomotor neurons and release acetylcholine
(ACh) at muscarinic receptors (M3) and VIP at VIP receptors
(VPACRs) on epithelial cells, or arterioles. VIP neurons are subdivided
according to their ability to generate cAMP as VIP/cAMP (+) and VIP/
cAMP (-) and may be further subdivided into VIP/cAMP/A2aRs and
VIP/cAMP/A2aR (-). Cholinergic neurons are ChAT/calretinin
(CALRET), CHAT/NPY, CHAT (-). Mechanical distortion such as
brush stroking the mucosa is one stimulus for activation of the reflex.
Myenteric secretomotor neurons project to the mucosa as well. CGRP
calcitonin gene-related peptide, EC enterochromaffin cells, 5-HT 5-
hydroxytryptamine, NK1 neurokinin-1, NPY neuropeptide Y, SP
substance P, A2aRs adenosine A2a receptors. (Modified from [25] by
permission)
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release acetylcholine or VIP to activate the chloride-
secreting crypt epithelial cells expressing muscarinic and
VIP receptors. All cellular components of this reflex have
functional adenosine (P1) or nucleotide (P2X and P2Y)
receptor subtypes and are the subject of this review.
Purinergic receptors
Adenosine, adenosine 5′-triphosphate (ATP), ADP, AMP,
uridine 5′-triphosphate (UTP), UDP, and UDP-glucose are
endogenous purines that activate P1, P2X, or P2Y
purinoceptor families that are widely and differentially
distributed in the ENS and non-neuronal cells in the GI
tract. The tissue distribution and/or biological experiments
suggest that up to 14 of 18 purinoceptors may be involved
in secretomotor reflexes in the GI tract. Still, our knowl-
edge remains incomplete.
Adenosine interacts with four cell surface P1 receptors,
designated as A1, A2a, A2b, and A3 receptors to influence a
variety of physiological functions. The endogenous ligand is
adenosine (or AMP, [41]). Receptor classification is based on
receptor cloning, pharmacological studies, and mouse recep-
tor knockout models. All four receptors are expressed in the
GI tract, but their characterization is incomplete (see later).
Adenosine receptors belong to the superfamily of seven
transmembrane domain G protein-coupled receptors (GPCR)
and they are emerging as potential therapeutic targets [53].
The nomenclature for the transmitter-gated ion channel
P2X1-7 receptors relies mostly on recombinant receptor
pharmacology as reviewed by Khakh et al. [57]; the
pharmacology of the P2X receptors in whole tissues is
complicated by species differences, marked ectonucleotidase
activity that interferes with agonist/antagonist potency
profiles, and lack of very selective ligands for P2X receptor
subtypes. Their review covers the functional properties of
recombinant receptors, their pharmacology, ion effects (Zn2+,
H+, Ca2+), and some native receptors in tissues.
A recent review summarizes the pharmacological profiles
of cloned mammalian metabotropic P2Y receptors [110] that
have been shown to mediate actions of nucleotides when
expressed in functional systems. Eight P2Y receptors have
been cloned and defined functionally. The P2Y1, P2Y2,
P2Y4, P2Y6, and P2Y11 receptors are coupled to stimulation
of phospholipase C (PLC). P2Y12, P2Y13, and P2Y14
receptors are negatively coupled to adenylyl cyclase (AC);
the P2Y11 receptor is positively coupled to AC. Abbrachio et
al. [1] provide an update on molecular mechanisms,
pathophysiology, and therapeutics of P2Y receptors.
P2Y1 receptors are involved in platelet aggregation,
vasodilation, neuromodulation, mechanosensitivity, and secre-
tomotor reflexes. The P2Y1 receptor is activated by ADP or its
analog 2-methylthioADP (2MeSADP). A potent and selective
antagonist is 2′-deoxy-N6-methyladenosine-3′5′-bisphosphate
(MRS2179) or MRS2279. Adenosine 5′-O-(1-boranotriphos-
phate) (ATP-α-B) derivatives are novel P2Y1 receptor
agonists that may be of potential clinical relevance [78].
The P2Y2 receptor plays an important role in Cl
- secretion
from epithelial cells, and a P2Y2 receptor agonist diquafosol
is used for treatment of dry eye disease. It is activated by
UTP and ATP and their actions are blocked by suramin,
although suramin has affinity for non-purinergic receptors as
well [54]. The P2Y4 receptor is expressed in epithelia, and
depending on the species, the receptor has a strong
preference for UTP (human receptor) or equal preference
for UTP and ATP (rat receptor). Unlike the P2Y2 receptor it
is not blocked by suramin. The P2Y6 receptor is distributed
in the cardiovascular system and brain. It has a preference for
UDP and 1,2-di-(4-isothiocyanatophenyl)ethane (MRS2567)
is a selective antagonist. UDP also acts on receptors for
cysteinyl leukotrienes. The P2Y11 receptor is blocked by
suramin (and reactive blue 2) and it prefers ATP as an
agonist. P2Y12 and P2Y1 receptors are similar in that
they are both activated by ADP and more potently by
2MeSADP. P2Y12 receptor antagonists are effective in
clinical use to inhibit platelet aggregation; the receptor is
also involved in inhibition of neuronal cells. Antagonists
include N6-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-
βγ-dichloromethylene-ATP (AR-C6931MX or cangrelor),
AZD6140, and active metabolites of clopidogrel and
prasugrel. The P2Y13 receptor is found in nerve cells and
immunocytes and is activated similar to the P2Y12 receptor,
but is selectively blocked by 6-(2′-chloro-5-nitro-azophenyl)-
pyridoxal-α5-phosphate (MRS2211). The P2Y14 receptor is
activated by UDP-glucose.
Sensory enterochromaffin cells
5-HT release from EC cells activates secretory, peristaltic, and
vasomotor reflexes and contributes to the coordination of
these reflexes. As shown in Fig. 2, EC cells with long basally
located fine projections containing serotonin and sometimes
connecting to neuron-like structures could be observed; other
cells had short blunt processes or were dividing EC cells. A
provocative possibility is the recent speculation that EC cells
may even function as primary neurons [44].
EC cell dysfunction is implicated in malignant carcinoid,
dumping, and irritable bowel syndromes, as well as IBD. 5-
HT secretion from carcinoid tumors is one of the putative
mediators of carcinoid diarrhea that can be relieved by 5-HT
antagonists. 5-HT3 antagonists or a partial 5-HT4 agonist
(i.e., tegaserod) are beneficial in treating diarrhea and
constipation predominant symptoms in patients, respectively
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[4, 67, 97]. Mucosal defects in 5-HT signaling occur in
ulcerative colitis, diarrhea (or constipation) predominant
IBS [24] or experimental colitis [67]. A better under-
standing of the signaling mechanisms, function, and
dysfunction of EC cells is essential in understanding gut
reflexes and symptoms of several diseases.
Despite the obvious importance of EC cells and 5-HT
release in normal or disease states, our understanding of
purinergic or other mechanisms involved in the regulation
of 5-HT release is limited. Tissue studies are of limited use
in helping us understand the complex regulation of 5-HT
release because of potential interference from mediators
released from neighboring cells. The human carcinoid BON
cell line is a suitable EC cell model to study receptor and
intracellular signaling pathways regulating 5-HT release
[34].
A clone of BON/EC cells that is 99% enriched in 5-HT
is a suitable EC model for population responses or for
single cell functional studies. BON cells retain many of the
mechanosensitive and chemosensitive properties of non-
transformed cells, they respond to nutrients (glucose),
mechanical activation (shaking, touch, stretch, volume
changes, pressure), as well as receptor activation (puriner-
gic, muscarinic, neurotensin, 5-HT, VIP, adrenergic,
somatostatin, cholecystokinin, dopamine, bradykinin, etc.).
A comparison of EC and BON cells indicates similarities in
expression of receptors, ion transporters, ion channels,
chemical mediators, or other mechanisms reviewed by
Cooke and Christofi [25]. In addition to 5-HT, they
secrete or contain adenosine, ATP neuron-specific enolase,
synaptophysin, chromogranin A, neurotensin, vasoactive
intestinal peptide (VIP), prostaglandins, and others. BON
cell injection into nude mice can also serve as a model of
carcinoid tumors [35].
Chemosensitivity of EC cells
EC cells have microvilli protruding into the lumen raising
the possibility that they may “taste” the luminal contents.
The nutrient monosaccharide D-glucose (10-100 mM) or
the nonmetabolizable α-D-glucopyranoside (not fructose)
caused a graded increase in 5-HT release in BON cells that
was not caused by changes in osmolarity. Phloridzin
blocked the effect of D-glucose by blocking D-glucose
uptake [59, 87]. The role of purinergic modulation of
nutrient activation of 5-HT release remains unknown.
Mechanosensitivity of EC cells
Mechanosensitivity in EC cells is poorly understood and
the mechanosensitive elements remain unknown. Brush
stroking, compression of the mucosa or villi, rotational
stroking, or pressure/volume changes used to evoke
mucosal secretomotor reflexes in the gut are not suitable
to elicit 5-HT release in isolated EC/BON cells. Mechanical
forces in the gut are complex and likely represent a
composite of forces (pressure, shear force, centrifugal
force, stretch, deformation, compression, touch, etc.). We
succeeded in employing three different mechanical stimuli
to elicit responses in EC cells to study purinergic regulation
of mechanosensitive 5-HT release. Rotational shaking of
cultured cells simulates forces that are generated in the
intestinal lumen (i.e., shear forces, centrifugal forces,
changes in hydrostatic pressure) and releases 5-HT. Pres-
sures of 75 mmHg or greater (normally associated with
painful stimulation) applied to cells in a pressure chamber
or laminar shear stress of 1–2 dyne/cm2 applied in a parallel
plate flow chamber evoked 5-HT release [26].
Second messengers in mechanosensitivity
Balloon distension and puffs of nitrogen gas/pressure
stimulate 5-HT release and trigger a reflex secretory re-
sponse via submucous neurons in intact mucosa/submucosa
preparations [84]. Rotational shaking of tissue preparations
or the EC/BON cells in culture predominantly activates a
Gαq/PLC/inositol triphosphate (IP3)–Ca
2+ signaling path-
way leading to 5-HT release [59]. A separate Gs/Gi/AC/
Fig. 2 Photomicrographs showing serotonin immunolabeled, formalin-
fixed EC cells dispersed from the colonic mucosa. All cells have luminal
projections. From the left, four serotonin-positive cells with one or two
basally located, axon-like projections are seen. The fourth of these cells
connects with a neuron-like structure. Right: a cell with short and blunt
basal projections. The EC cells are in some cases attached to
neighboring mucosa cells. (Modified from [44] by permission)
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PKA (protein kinase A)/cAMP signaling pathway provides
a minor contribution to mechanosensitive 5-HT release
[18].
Dual modulation of mechanosensitivity by P2Y1
and P2Y12 receptors
Recent evidence from pharmacological and molecular
studies support the hypothesis that dual modulation of 5-
HT release occurs via excitatory P2Y1 receptors coupled to
the Gαq/PLC/IP3-Ca
2+ signaling pathway leading to 5-HT
release [114] and inhibitory P2Y12 receptors coupled to AC
(Christofi, Wunderlich, Xue, Cooke, unpublished observa-
tions; [120]). Touch/stretch evokes a Ca2+ response in
BON/EC cells that is used to study purinergic regulation of
mechanosensitivity. In preliminary studies, touch Ca2+
responses in EC cells were inhibited by apyrase (ectonu-
cleotidase) whereas a 5′-ectonucleotidase inhibitor ARL
67156 augmented responses indicating that a nucleotide is
involved in mechanosensitivity. When single cells are
examined and analyzed according to inhibition or augmen-
tation of the Ca2+ response, dual modulation of the
response is revealed in subsets of EC cells. Therefore, the
P2Y1 receptor antagonist MRS2179 could either abolish
the touch Ca2+ response or augment the response in different
subsets of EC cells. MRS2179 could block touch-evoked
Ca2+ responses in cells responsive to the P2Y1 receptor
agonist 2MeSADP. The Ca2+ response evoked by 2MeSADP
was either inhibited or augmented by MRS2179 in subsets of
EC cells; an additional component of the touch Ca2+
response was blocked by the P2 receptor antagonist PPADS
[114].
In molecular signaling studies, when the human P2Y1
receptor was overexpressed in BON cells with naitive P2Y
receptors, it caused additional mobilization of Ca2+ in the
cells and augmented 5-HT release. A P2Y1 receptor
silencing RNA reduced receptor expression leading to a
reduction in 5-HT release. In heterologous 1321N1 cells,
transfection of human P2Y1 receptors enabled the cells to
generate a Ca2+ response to mechanical stimulation. P2Y1
receptor antagonists MRS2179 or A3P5P abolished the
Ca2+ response in 1321N1 cells or 5-HT response in BON
cells that overexpressed the human P2Y1 receptor [120].
Overexpression of the P2Y12 receptor in BON cells and/or
HEK293 cells nearly abolished mechanically evoked 5-HT
release (BON) and cAMP (both cell types). Blockade of
P2Y12 receptors by 2-MeSAMP augmented the cAMP
responses. 5-HT release was augmented after knockdown
of P2Y12 receptors in BON cells; silencing of P2Y13
receptors had no effect. Therefore, molecular studies are
consistent with pharmacological studies and suggest that
dual purinergic modulation of mechanosensory signaling via
P2Y1 and P2Y12 receptors (that recognize both MRS2179
and 2MeSADP) leads to 5-HT release in EC cells. The P2Y1
and P2Y12 receptors may provide new targets for modula-
tion of mucosal secretory reflexes and are potential
therapeutic targets, as shown for platelets [1]. The role of
other receptors expressed in EC/BON remains unknown.
Messenger RNA transcripts for P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y12, and P2Y13 exist in BON cells [25, 26].
Adenosinergic modulation of 5-HT release
Endogenous adenosine modulates the basal release of 5-HT
from EC/BON cells. Adenosine deaminase caused a dose-
dependent increase in 5-HT release (Fig. 3a). The nucleoside
uptake inhibitor S-(p-nitrobenzyl)-6-thioinosine (NBTI) pre-
vented mechanically evoked 5-HT release (Fig. 3b) by
elevating endogenous adenosine (Fig. 3c). Overall, endoge-
nous adenosine is sufficient to provide ongoing inhibition of
basal and mechanically evoked 5-HT release. The adenosine
A3 receptor is activated by endogenous adenosine since
baseline 5-HT release was augmented by an A3 receptor
antagonist MRS1191 and this was sensitive to an A3 receptor
agonist IB-MECA (Fig. 3d); the A3 effect was restricted to
the Ca2+ signaling pathway. The A1 receptor also contributes,
and an A1 receptor antagonist (CPT), an A3 receptor
antagonist (MRS1191), or adenosine deaminase could also
augment the touch/stretch Ca2+ response (Fig. 3e). Touch Ca2+
responses occur via a Gαq/PLC/IP3 pathway that is the
predominant mechanism in 5-HT release from EC cells. 5′-N-
methylcarboxy aminoadenosine (MECA) elevated both 5-HT
and cAMP levels in BON cells. A2 receptor antagonists could
suppress mechanically evoked 5-HT release indicating the
endogenous adenosine can contribute to stimulation of 5-HT
release via A2 receptors. Together, these and other findings
indicate that endogenous adenosine can activate inhibitory A3/
A1 receptor–Gαq/PLC/IP3–Ca
2+ and excitatory A2a/A2b re-
ceptor–AC/cAMP signaling pathways on EC cells to regulate
5-HT release; A1, A2a, A2b, and A3 receptors or mRNA
transcripts are present in both BON/EC cells, gastric and
intestinal 5-HT-ir carcinoid tumors [18]. Recent isolation of
ileal EC cells [58] may permit further study and comparison
of purinergic signaling mechanisms in normal and diseased
human ileum. Real-time electrochemical detection of local
mucosal 5-HT release is also very promising [5].
Intestinal secretory reflexes
Hubel’s [51] pioneering spirit and studies demonstrated that
electrical field stimulation of tissue setup in Ussing
chambers can stimulate transepithelial short-circuit current
(Isc) changes indicative of ion transport. His studies
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provided proof that submucous neurons could regulate
chloride secretion. This sparked the beginning of a new era
of investigation on the influence of the ENS on epithelial
secretion and secretomotor reflexes.
The secretory reflex can be activated by nutrients or
mechanical stimulation or exposing the gut to food antigens
regarded as foreign or to enteropathogenic microorganisms.
The mucosal surveillance and immune defense system is
exposed to an estimated 1012 different antigens per day that
mobilizes both intrinsic and extrinsic nervous systems,
hormones, paracrine substances, and immune mediators to
modulate chloride secretory rates.
The net flux of ions into the gut lumen is the balance of
secretion and absorption. Basal secretion or “secretory
tone” is also the net flux of ions and fluid into the intestinal
lumen that is dependent on the spontaneous release of
endogenous paracrine, autocrine, or neurocrine mediators.
Secretory tone is assessed from changes in basal Isc, a
measure of chloride secretion. The basal Isc is under
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Fig. 3 Regulation of 5-hydroxytryptamine (5-HT) release by endog-
enous adenosine release from BON cells via inhibitory A1/A3
receptors and excitatory A2 receptors. a The enzyme ADA caused a
dose-dependent increase in 5-HT release, indicating that release of
endogenous adenosine provides an ongoing inhibition of 5-HT
release. b In the same cells as a, NBTI blocked adenosine uptake
and abolished mechanically evoked 5-HT release. c Adenosine release
during resting/unstimulated conditions (Base) and mechanical stimu-
lation (MS) is augmented in the presence of the adenosine uptake
inhibitor S-(p-nitrobenzyl)-6-thio-inosine (1 μM NBTI). d Chemical
stimulation with IB-MECA decreased basal 5-HT and the A3R agonist
cAMP levels. The A3R antagonist MRS1191 (10 nM) augmented 5-
HT release but not cAMP levels (p<0.05). The MRS1191-evoked 5-
HT response was sensitive to IB-MECA inhibition. e Adenosine A1
and A3R inhibitory components of touch-evoked Ca
2+ responses in
enterochromaffin/BON cells. The A3R antagonist MRS1191 aug-
mented the touch Ca2+ transient. Chronic exposure to the A1
antagonist CPT for 24 h caused a significant augmentation in the
touch Ca2+ response. The stimulatory effects of CPT and MRS1191
were additive on the touch Ca2+ response. Adenosine deaminase
(5 units/ml)-induced augmentation is reduced by the A3R agonist IB-
MECA (50 nM). f A2A/A2B antagonists CGS and AL (alloxazine)
inhibited mechanically evoked 5-HT release. Baseline values (pmol/
well per 30 min) of 5-HT and/or cAMP are at the top of figures with
the number of experiments indicated in parentheses. IB IB-MECA,
MRS MRS1191, ME MECA, AL alloxazine, CGS CGS 21680, MS
mechanical stimulation by rotational shaking at 80 rpm, NS not
significant. (Modified from [59] by permission)
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nists (PPADS, suramin) or P1 receptor antagonists (CPT),
nucleotidases, or nucleotidase inhibitors indicated that
endogenous nucleotides stimulate, while endogenous aden-
osine inhibits basal Isc [29]. However, basal secretion is not
affected by P2X or P2Y1 receptors because neither of
NF279 or MRS2179 influenced Isc. Overall, adenosine,
nucleotides, somatostatin, and prostaglandins all contribute
to “secretory tone” [26, 27].
P2Y1 receptors and mucosal stroking-evoked
neurosecretory reflexes in the colon
Mechanical or chemical activation of the mucosa can lead
to an intestinal neural reflex and an increase in ion transport
and fluid secretion. Very few studies have investigated
purinergic regulation of secretomotor function [18, 27–29].
Mucosal distortion by brush stroking or distension can elicit
the reflex (Fig. 4).
Brush stroking of the mucosa causes an intestinal neural
reflex response and an increase in Isc indicative of
electrogenic chloride ion transport. The brush stroking reflex
in the rat colon mucosa-submucosa is reduced by MRS2179
or apyrase and further inhibited by tetrodotoxin (TTX).
2MeSADP, a mixed P2Y2/P2Y4 agonist UTP, or ATP (P2
receptor agonist) evoked neural and non-neural secretory
responses. Mucosal touch/distension evoked fluo-4/Ca2+
responses in submucous neurons were also inhibited by
apyrase or blocked completely by MRS2179 (Fig. 5);
MRS2179 only reduced Isc in stroking reflexes. The potency
profile of nucleotides for reducing Isc is different from that
for touch Ca2+ responses [18]. P2Y1 immunoreactivity was
identified in a majority of VIP, NOS, calretinin, NPY, or
somatostatin neurons but not SP or calbindin submucous
neurons. P2Y4 immunoreactivity occurred mainly in the cell
somas of NPY neurons (93%). P2Y2 immunoreactivity
occurred in a minority of SP, VIP, NPY CGRP varicose
fibers (5-20%) and those surrounding calbindin neurons [18,
26]. Purinergic responses could be distinguished based on
stroking reflexes, touch-evoked Ca2+ reflexes, actions of
nucleotides, or sensitivity to antagonists. These and other
data suggest that several nucleotides may contribute to
mechanically evoked secretomotor reflexes. Nucleotides
differentially activate P2Y1, P2Y2, and P2Y4 receptors
located at putative pre- or postsynaptic sites on submucous














Dissention – Fluid Removalc
CLAMP
Stopcock
Remove aliquot & replace
PD
Isc
Fig. 4 Modified Ussing chambers used for mucosal stroking studies
to evoke a reflex neurosecretory response. a Vertical configuration of
the chamber permits a 2-mm brush to be placed on the mucosal
surface. A single stroke represents the directional movement of the
brush from one side to the other on the surface of the mucosa. b A
complete 360° turn of the brush is another variation for stimulating
reflexes; stroke (1 s) is reproducible every 5 min for a 40-min period. c
Distention is accomplished by removing small volumes of fluid from
the serosal side. Drugs are perfused separately on the serosal or
mucosal surfaces of the mucosa-submucosa or whole thickness colonic
or small bowel tissues. The Isc/short-circuit current nulled out the
spontaneous potential difference (PD) and was used as a measure of
chloride secretion in the distal colon. (Modified from [25] by
permission)
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P2Y1, P2Y2, and P2Y4 receptors to inhibit glutamate release
[91]; presynaptic P2Y1 and P2Y2 receptors also occur in the
rat submucous plexus. A working model of the purinergic
neural circuitry in the rat colon is shown in Fig. 6.
ARL 67156 augmented, whereas apyrase, atropine, or
TTX could inhibit stroking-evoked reflex Isc responses in
guinea pig distal colon (Fig. 7a). The agonist potency
profile of 2MeSADP > UTP ≥ UDP for stimulation of
neural secretion supports a P2Y1 receptor (Fig. 7b), but
does not exclude others. MRS2179 reduced the stroking
response by 54% and the effect of 2MeSADP by 70%. P2
receptor antagonists PPADS and suramin had additive
inhibitory effects. The P2X1/3 receptor agonist αβMeATP
caused stimulation of Isc, and a desensitizing concentration
reduced stroking-evoked secretion but did not affect the
2MeSADP response. Cell bodies of guinea pig colonic
submucous neurons expressed P2Y immunoreactivity.
About 20-50% of submucous neurons expressed P2Y1
and P2Y2 receptors. P2Y immunoreactivity (P2Y1, P2Y2,
or P2Y4) was virtually undetectable in any varicose
fibers. P2Y1 immunoreactivity was abundant in putative
cholinergic secretomotor neurons and fewer than 2% of
NPY/cholinergic secretomotor neurons [71]. In contrast,
P2Y2 immunoreactivity was found in all NPY secretomotor
neurons and 30% of calbindin/intrinsic sensory neurons.
P2Y4 is of minor significance in submucous neurons. In
guinea pig, mucosal stroking may activate putative P2X1/3,
P2Y1, and P2Y2 receptors located at postsynaptic mem-
branes of submucous neurons leading to chloride secretion;
P2Y1 receptors on EC also contribute. Based on the
available evidence, it was hypothesized that a separate
P2Y2 neural circuit pathway exists in guinea pig that is not
activated by stroking the mucosa [25, 27]. In both rat and
guinea pig, receptors or mRNA transcripts exist for P2Y1,
P2Y2, P2Y4, P2Y6, and P2Y12 receptors in the submucosa,
and therefore influence of other receptors in stroking
reflexes deserves further attention. Species differences exist
between mucosal stroking reflexes in rat [18] and guinea
pig [27] distal colon in purinergic regulation, and no
information exists for the human GI tract.
Neurogenic mucosal secretion and P2Y1 receptors
in small intestine
In the guinea pig small intestine, it was shown that
neurogenic mucosal secretion is mediated by the P2Y1
receptor that may be expressed on VIP secretomotor
neurons. MRS2179 blocked the neurally mediated ATP-
evoked response with an IC50 of 0.9 μM. TTX could
suppress or abolish the ATP response. The P2Y1 receptor
was coupled to PLC/IP3/Ca
2+–calmodulin/protein kinase C
signaling pathway [37] like that on EC/BON cells.
Purinergic modulation of local inhibitory reflexes
Local inhibitory reflexes to the circular muscle evoked by
mucosal application of nutrient amino acids in guinea pig
jejunum are partially blocked by antagonists to P2X
receptors suggesting involvement of ATP [46]. The receptor
subtype(s) have not been characterized. Effects of nutrients
on local secretomotor reflexes and involvement of purinergic
signaling in the coordination of motility and secretion remain
unclear, although some data are emerging on adenosine A3
and A1 inhibitory receptors (see later section on “Neurogenic
diarrhea”; [8, 9]).
Fluo-4/Ca2+ imaging studies are providing new insights
into the functional purine receptors involved in the
excitability and synaptic transmission in intact neural
circuits of the submucous plexus of the human gut. A
recent study indicated that the submucous plexus from
Roux-en-Y patients is a suitable model to study synaptic
transmission in the human enteric nervous system [115]. It
was shown that the P2Y1 Gαq-PLC/IP3 Ca
2+ signaling
Fig. 5 Laser confocal imaging of touch-induced purinergic Ca2+
signals in neurons of the intact microdissected submucous plexus of
the rat distal colon. a Perfusion chamber used to record touch-induced
Ca2+ responses in the neurons. It includes a recording chamber made
of a 35-mm microwell dish with a 1-cm, number 0.0 cover glass in the
center of the bottom of the dish for visualizing the fluorescent
neurons. A portion of the dish is embedded with a 2-mm thick layer of
Sylgard shaped around a half moon at one end of the dish. Perfusion
with oxygenated buffer or drugs is exactly opposite to the suction. The
microdissected M-SMP preparation is stretched and fixed with many
(15-20) micropins along the Sylgard layer. The remaining SMP
without mucosa is stretched over the glass cover slip of the dish and
secured with magnetic metal feet (not shown). A large ganglion of the
intermediate layer of the submucous plexus is viewed with a 40× oil
immersion objective (N.A. 1.3). b Inset shows Fluo-4/AM loaded
neurons representing second order neurons that are visualized. c Side
view of the tissue: The submucous plexus layer is located flat on the
bottom of the dish and the mucosa/submucosa lifts over the Sylgard
ends at each side of the half moon. The tissue is touched for 20 s on
the mucosal surface of M-SMP portion that is stretched across the
Sylgard with a fire-polished glass pipette to evoke a Ca2+ response in
the neurons—the tissue is free to move/stretch downward during the
touch, since it is located a distance of 2 mm above the glass bottom.
d–g The P2Y1 antagonist MRS2179 or TTX abolish the touch-
induced Ca2+ fluorescence response. A representative example of the
effects of MRS2179 and TTX on touch-induced Ca2+ transients in a
single ganglion (seven neurons in one ganglion). A 20-min exposure
to the selective P2Y1 antagonist MRS2179 (10 μM) abolished the
touch response in the neurons. In the presence of 0.2 μM TTX,
the touch response decreased to below baseline levels. Arrows
indicate touch-responsive cells. h Pooled data for the peak effects of
MRS2179 and TTX; averaged transients from 30 neurons from 3 to 4
separate ganglia. i Breaking down endogenous nucleotides reduces the
touch-induced Ca2+ response in the neurons of the intact M-SMP. The
touch response was determined in the presence of 5 units/ml apyrase
exposed for 10 min. Apyrase reduced by 50% the control touch
response (n=4 neurons, p<0.01). Values are means ± SEM. (Modified
from [18] by permission)
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pathway, N-Ca2+ channels, nicotinic receptors, and extrin-
sic nerves are involved in neurotransmission. Pharmaco-
logical findings suggest that inhibitory adenosine A3
receptors modulate nucleotide and cholinergic transmission
in the human enteric nervous system.
In the guinea pig small intestine, electrophysiological
studies revealed that AMP activates presynaptic inhibitory
A1 receptors to suppress neurotransmission and postsynaptic
A2a receptors to elicit a slow excitatory postsynaptic
potential (EPSP)-like response. Signaling pathways coupled
to A2a receptors include AC, PLC, PKC, and calmodulin-
dependent kinases [41]; whether AMP can also activate A2b
or A3 receptors remains unclear.
Endogenous adenosine and A1 receptors in mucosal
reflexes
The role of endogenous adenosine in the physiological
regulation of mucosal secretory reflexes was investigated
in pharmacological studies [29]. At nanomolar concen-
trations, the A1 antagonist 8-chlorophenyltheophylline
(CPT) caused a concentration-dependent enhancement of
the stroking reflex. The effect still occurred in the presence
of an A2a receptor antagonist 8-(3-chlorostyrl) caffeine.
Adenosine deaminase (5 U/ml) also enhanced the reflex
secretory response, whereas the nucleoside uptake blocker
NBTI inhibited it. The A1 receptor agonist 2-chloro-N6-
cyclopentyladenosine (CCPA) inhibited reflex-evoked Isc
(Fig. 8a; EC50=6 nM) and its effect was also blocked by
CPT. In experiments with either piroxicam to block the
prostaglandin (PG)-mediated pathway or N-acetyl-5-
hydroxytryptophyl-5-hydroxytryptophan amide to block
the 5-HT mediated pathway, CCPA reduced or abolished
the residual reflex Isc response (Fig. 8b). CCPA could
abolish the reflex response to a pulse of 5-HT (Fig. 8c)
without affecting TTX-insensitive epithelial responses to
carbachol or forskolin. A1 immunoreactivity was expressed
in submucous neurons, in presynaptic varicose nerve
endings (synaptophysin-positive neurons), and in glia. The
chemical coding of those submucous neurons is not known.


































Mechanical Activation of Purinergic Neural Circuitry in Rat Distal Colon
P2Y1R
Fig. 6 Mechanical activation of purinergic neural circuitry in rat distal
colon. Mucosal brush stroking or touch/stretch releases nucleotides
that may include ATP, UTP, and ADP that activate neural P2Y1, P2Y2,
and P2Y4Rs at pre- or postsynaptic sites of submucous neurons
leading to a net increase in Isc/chloride secretion. Intrinsic primary
afferent neurons do not express P2YRs on their cell somas, but receive
strong synaptic inputs from extrinsic fibers (i.e., pelvic origin) with
P2Y2Rs forming baskets of varicose fibers surrounding their cell
somas. A very tiny subset of VIP secretomotor neurons expresses
P2Y2R. P2Y2Rs, P2Y1Rs, and P2Y4Rs are coexpressed on >90% of
NPY/VIP putative secretomotor neurons that also express SP Rs.
P2Y1Rs are also expressed on putative somatostatin (SOM) neurons.
Activation of P2Y1Rs leads to a rise in intracellular free Ca
2+ levels in
the secretomotor neurons by ATP, UTP, or ADP. A nicotinic
cholinergic synapse has not been ruled out. NOS neurons and
CALR/CHAT cholinergic neurons also express P2Y1Rs, but the
functional role of these subsets of neurons is unknown. P2Y2Rs are
discretely localized on some extrinsic fibers of SP, VIP, NPY, CGRP,
or cholinergic origin presumed to be involved in synaptic modulation
of transmitter release. (Modified from [18] by permission)
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provides a physiological brake to suppress reflex-evoked
Cl- secretion elicited by stroking the mucosa by acting at A1
receptors located on EC cells [17, 18] and in the ENS [29].
Adenosine acts at A1 receptors to suppress both the PG and
5-HT sensory limbs of mucosal secretory reflexes [29]. Our
understanding of the role of A1 receptors in the modulation
of mucosal reflexes is restricted to the guinea pig colon;
however, it is likely this effect will occur in other regions,
given that the A1 receptor provides inhibition of synaptic
transmission in myenteric and submucous neurons, and in
other regions including stomach antrum, jejunum, and
ileum [8, 20, 22].
Distribution of adenosine, P2X, and P2Y receptors
and gene products in ENS
Immunohistochemical, gene chip microarray, quantitative
reverse transcriptase polymerase chain reaction (RT-PCR),
or in situ hybridization data have identified various
purinergic receptors in the gut of various species. These
include A1, A2a, A2b, A3, P2X2, P2X3, P2X5, P2X7, P2Y2,
P2Y4, P2Y6, P2Y12, and P2Y14 receptors in the ENS of
guinea pig, mouse, rat, or human intestine [14, 17–19, 25,
27, 29, 49, 93, 94, 108, 109, 117–119].
Differential gene and receptor expression of adenosine
A1, A2a, A2b, and A3 receptors in the human enteric
nervous system
Adenosine A1, A2a, A2b, and A3 receptor gene products
were differentially expressed in neural and non-neural
layers of the human jejunum, ileum, cecum, and colon as
well as T-84, HT-29, T98G, and BON/EC cells or in PGP
9.5-ir enteric neurons [19]. Table 1 summarizes adenosine
receptor mRNA expression levels in the different layers and
cells using RT-PCR. With the exception of the A1 receptor,
mRNA transcripts for A2b, A2a, and A3 receptors are
expressed throughout the GI tract in epithelial cells,
mucosa, and submucosa suggesting a significant role in
secretomotor behavior of the human gut.




















































































































Fig. 7 Mucosal stroking releases endogenous ATP/nucleotides that
activate excitatory neural P2Y1Rs leading to an increase in Isc/chloride
secretion in the guinea pig colon. a The ATPase/5′-nucleotidase inhibitor
6-N,N-diethyl-β,γ-dibromomethylene-D-adenosine-5′-triphosphate triso-
dium (10 μM, ARL 67156 or ARL) prevents hydrolysis of ATP and
enhanced reflex-evoked Isc (n=6, *p<0.05), whereas 10 U/ml apyrase
hydrolyzes ATP and inhibited reflex-evoked Isc responses (n=4). This
indicates that endogenous nucleotide release contributes to the stroking
response. b Concentration-response curves for nucleotides in the
presence of 1 μM CPT (n=4-23), an A1 receptor antagonist used to
block eADO effects. The rank order of potencies of nucleotide agonists
for stimulation of Isc was 2MeSADP = 2MeSATP > UTP = UDP that
indicates a P2Y1R interaction. c The selective P2Y1R antagonist
MRS2179 suppresses ~50% of the stroking response. d The Isc
response to the P2Y1R agonist 2MeSADP was nearly abolished by the
P2Y1R antagonist MRS2179 (10 μM, n=4, p<0.05). All experiments
were done in the presence of 1 μM CPT to eliminate inhibitory influence
of A1 receptor activation by endogenous adenosine (n>/4, *p<0.05)
(Modified from [27] by permission)
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Cellular localization of adenosine receptor immunoreac-
tivity is summarized in Table 2. Adenosine A3 immunore-
activity is also expressed in a majority of substance P
(~60%) and < 10% of VIP submucous neurons. In contrast
to A3R receptors, A2b immunoreactivity is prominent in
50% of VIP neurons and not expressed in SP neurons
in jejunum, but is expressed mainly in non-VIP neurons in
colonic submucous neurons. Therefore, A2b receptors and
A3 receptors may serve different roles in secretomotor
function in the two regions by acting at putative secreto-
motor or sensory neurons, respectively.
A2a immunoreactivity is found in a subset of VIP
neurons. Varicose fibers in submucous ganglia label for
A2a or A2b immunoreactivity. A2a and A2b immunoreactivity
is prominent in submucous neurons, but only expressed in a
minority of myenteric neurons. Immunoreactivities for A2a
and A2b receptors are colocalized in submucous neurons of
the jejunum and colon (and jejunal myenteric neurons) as
well as in epithelial cells of the jejunum (only region
studied). A2b immunoreactivity was also intensely expressed
in s-100 positive glia in both nerve plexuses.
A1 immunoreactivity is abundantly expressed in sub-
mucous neurons of the colon, but was undetectable in
submucous neurons of the jejunum. This is consistent with
functional studies on synaptic Ca2+ responses in submucous
neurons illustrating a lack of effect of A1 receptor antagonists
Fig. 8 Effect of CCPA on stroking-evoked change in Isc. A
Concentration-response curve (EC50=6 nM, n=3-6). B Effect of
CCPA (0.1 μM) on 5-HT- and PG- mediated limb of reflex pathway. a
Presence of 5-HT limb after blockade of prostaglandin synthesis with
10 μM piroxicam (PIR) (n=5). b Presence of PG limb after blockade
of 5-HT limb with 1–10 μM N-acetyl-5-hydroxytryptophyl-5-hydrox-
ytryptophan amide (HTP) (n=6 or 7). Con control, p<0.05 from
control and PIR or HTP. C Effect of CCPA (0.1 μM) on change in Isc
evoked by a mucosal pulse of 5-HT (1 μM) (n=3); p<0.05 (Modified
from [29] by permission)
Table 1 RT-PCR to detect human adenosine receptor mRNA in
human intestine
A1 A2a A2b A3
Jejunum
Whole thickness - (-) - (+)? ++ ++
Mucosa/submucosa - (-) ++ ++ +
Mucosa - (-) + ++ +
Mucosa - (+)? ++ ++ ++
Submucous plexus - (+) - (+) + +
Longitudinal/circular + (++) ++ ++ +
Ileum
Whole thickness + (+) ++ + +
Mucosa/submucosa ND ND ND ND
Mucosa - (+) ++ + +
Submucous plexus ND ND ND ND
Cecum
Whole thickness - (-) + ++ +
Mucosa/submucosa - (+) ++ + +
Mucosa - (-) + ++ +
Submucous plexus - (+) - (-) + - (+)
Colon
Whole thickness - (-) - (-) + - (+)?
Mucosa/submucosa - (-) - (-) ++ +
Mucosa ND ND ND ND
Submucous plexus - (+) - (+)? ++ +
Human cell lines
HT-29 (colonic epithelium) + (+) +++ +++ - (-)?
T-84 (colonic epithelium) - (+) + +++ - (-)?
T98G (glioblastoma) ++ +++ +++ - (+)
ND not done, + or – indicate receptor mRNA detected or not detected,
respectively. Failure to detect adenosine receptor mRNA after the first
round of PCR reflects either absence or low expression. If the results
of RT-PCR were negative, an aliquot of the first PCR reaction was
amplified a second time, and the result is indicated in parentheses.
Failure to detect adenosine receptor mRNA after the second round of
PCR is likely to be due to its absence. A question mark indicates a
possible faint expression of receptor mRNA. (Modified from [19] by
permission)
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expected to block ongoing inhibitory effects of endogenous
adenosine at neural receptors and enhance synaptic trans-
mission, as revealed in other tissues with functional A1
receptors (see later discussion; [9, 21]). In addition, strong
A1 immunoreactivity is found in epithelial cells of the human
colonic mucosal glands, and mRNA and proteins expressed
in two human epithelial cell lines. Therefore, A1 receptors
could potentially play a role in submucosal neural reflexes,
leading to suppression of intestinal secretion in the human
gut as reported for the guinea pig colon [29]. The diverse but
receptor-specific localization and expression of the four
adenosine receptors in submucous neurons, glial cells, or
epithelial cells, and the colocalization of A2a and A2b
receptors in submucous neurons or glandular epithelia,
suggests a prominent and complex role for adenosine in the
modulation of enteric neural reflexes that control secreto-
motor functions in the human digestive tract. Functional
studies on adenosine receptors in human gut would be of
physiological and clinical importance.
Distribution of P2X and P2Y receptors in the enteric
nervous system
P2X2 immunoreactivity has been identified in guinea pig
ENS [14, 50, 111]. In submucous ganglia of the guinea pig
ileum, P2X2 immunoreactivity occurred in all VIP-positive
neurons and calbindin-positive neurons making up about
50% of the neurons. In contrast, there was not any P2X2
immunoreactivity in NPY or calretinin-positive neurons.
Overall, P2X2R are expressed in both nerve plexuses, in
inhibitory motor neurons, IPANs of the myenteric plexus in
stomach and intestine, on gastric endings of vagal afferent
fibers, VIP noncholinergic secretomotor neurons, and
IPANs of the submucous plexus [14]. In contrast to P2X2,
P2X3 immunoreactivity in the submucous plexus occurs in
most calretinin neurons that represent cholinergic neurons
projecting to mucosa or arterioles, and make up ~12% of
the population [10]; therefore, the activity of some
secretomotor neurons is likely to be modulated by P2X3
receptors in guinea pig.
P2X2 and P2X3 immunoreactivity was also identified in
nerve fibers in enteric ganglia, interganglionic fiber tracts,
in the muscularis as well as in the perivascular plexus of
the guinea pig gallbladder. P2X2 or P2X3 neurons
displayed immunoreactivity for VIP (>90%) and NOS
(~50-60%) [93]. The function of these receptors remains
unknown.
P2X2 and P2X3 immunoreactivity was also localized in
rat ENS, by in situ hybridization or mRNA levels [119].
Receptors were identified throughout the GI tract in both
myenteric and submucous neurons. P2X2 immunoreactivity
(56% ileum, 45% distal colon) and P2X3 immunoreactivity
(62%, 40%) was abundant in submucous neurons. P2X2
immunoreactivity in submucous plexus colabeled for calbin-
din or calretinin in 30-50% of neurons. P2X3 immuno-
reactivity neurons expressed calretinin (40%) and calbindin
(30-75%). Coexpression of P2X3 immunoreactivity in
calbindin neurons also occurred in colorectum [116] but
not in those in rat ileum [85, 108]. At least in the mouse, AH
sensory (not S/type 1) neurons did express P2X3 immuno-
reactivity [7]. Species and region differences may exist in
distribution of the P2X2 and P2X3 receptors in submucous
neurons (see [7, 14, 49, 93, 111, 118]). The P2X1, P2X4, or
P2X6 receptor was undetectable in mouse ENS. The P2X5
receptor is widely distributed in mouse GI tract in enteric
ganglia in both nerve plexuses. In the submucous plexus,
P2X5 immunoreactivity discretely colocalize with 22% of
calretinin, 9% of calbindin, 6% of nitric oxide synthase, and
68% of VIP-positive neurons. Therefore, the P2X5 receptor
may be distributed in secretomotor and intrinsic sensory
neurons. The mouse P2X5 receptor could form heteromul-
timers with a unique pharmacology [94].
P2X3 immunoreactivity has also been identified in
submucous (and myenteric) neurons as well as in some
axons/dendrites of the human colon [36, 122], but the
identity of the subtypes of human neurons expressing P2X3
immunoreactivity remains unclear. Future studies should
include detailed analysis of the distribution of purinergic
receptors in the human ENS.
P2Y2 immunoreactivity occurs in neurons and fibers in
both myenteric and submucous plexuses in the corpus of
Table 2 Cellular localization of adenosine A1, A2a, A2b, and A3
receptor immunoreactivities in human small and large intestine
Human intestinal region/cell type A1 A2a A2b A3
Jejunum +
Longitudinal muscle ± ± -
Myenteric plexus neurons + + +
Glia - - +++
Circular muscle + - -
Submucous plexus neurons - +++ +++
Nerve fibers/neurites - + + +
Epithelia - + + +
Colon +
Longitudinal muscle ± - -
Myenteric plexus neurons - + +
Glia - - +
Circular muscle + + +





- absent, + present (or present ≤ 2 neurons), ± marginally detectable,
++ 3-6 neurons, +++ > 6 neurons. (Modified from [19] by
permission)
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the stomach, jejunum, ileum, and colon of the guinea pig
[118]. P2Y2 immunoreactivity is prominent in neurons with
Dogiel type I morphology. All P2X3 neurons and none of
the P2X2 neurons in the submucous plexus (or ~50% in
myenteric neurons) coexpressed P2Y2 immunoreactivity
throughout the GI tract. A majority of calretinin and NPY
submucous neurons also expressed P2Y2 immunoreactivity.
Submucosal neurons with P2X3 and P2Y2 receptor immu-
noreactivity with Dogiel type I morphology may represent a
subset of S/type 1 neurons with Dogiel type I morphology
that display both a fast P2X and slow P2Y membrane
depolarization [3]. It has been suggested that a P2X2 or
P2X7 receptors may mediate the fast P2X response in
neurons that only display a fast response [3, 14, 49, 119].
Lack of P2Y2 immunoreactivity in calbindin submucosal
neurons of the guinea pig gut argues against their
expression on IPANs [39]. Regional differences occur in
the colocalization of P2Y2 immunoreactivity with P2X3
immunoreactivity or in other types of neuronal markers.
These receptors may play a role in regulation of mucosal
secretory glands and the local vasculature.
The P2Y6 receptor is widely distributed in myenteric but
not submucous ganglia of the stomach, jejunum, ileum, and
colon (in guinea pig), whereas the P2Y12 receptor is also
widely distributed in submucous ganglia. P2Y12 and P2Y6
receptors and neurons likely play different roles in the gut.
A distinction between their localization is that P2Y12
immunoreactivity (not P2Y6) is also expressed in calbindin
intrinsic sensory neurons and not calretinin or NOS (in both
plexuses). P2Y6 immunoreactivity is instead found in NOS
and calretinin-positive neurons. Therefore, the P2Y12
receptor may play a role in sensory signaling in mucosal
secretomotor reflexes.
Mucosal epithelial cell lines and ion transport
In human epithelial carcinoma cell lines (HCT8 and Caco-2),
cells express mRNA for P2X1, P2X3, P2X4, P2X5, P2X6, and
P2X7 and P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, and P2Y12
receptors. In addition, P2Y1, P2Y2, and P2X1-7 receptor
proteins are expressed in these cells. Functional studies on
cell proliferation and apoptosis using selective agonists and
antagonists suggested involvement of P2X7, P2Y1, P2Y2,
and P2Y4 receptors but their role in secretion awaits further
study [31].
ENaC and CFTR channels
ENaC mediate electrogenic absorption of Na+ in intestine
(and other epithelial tissues). ENaC in colonic epithelia is
expressed together with the CFTR Cl- channels. Stimula-
tion of purinergic receptors by ATP or activation of CFTR
stimulate chloride secretion and inhibit amiloride-sensitive
Na+ transport (ENaC). Inhibition of ENaC by nucleotides is
not via CFTR-mediated ATP release [62]. ATP or UTP
acting at P2YRs also activate Ca2+-dependent Cl- channels.
Na+ absorption in mouse colon (and airway epithelia) is
inhibited by cell shrinkage (change in volume) by a
mechanism that does not interfere with purinergic (or
CFTR) mediated inhibition of ENaC [101]. A recent study
in P2Y2 and P2Y4 knockout mice suggests that only the
stimulation of the luminal P2Y2 receptor mediates inhibi-
tion of electrogenic Na+ absorption via epithelial Na+
channels (ENaC) in mouse colon. In contrast, luminal
P2Y2 and P2Y4 receptors stimulate K
+ secretion [74].
Luminal P2 and ion transport
P2 receptors are found in both the basolateral and luminal
membranes. A recent review by Leipziger (2003) summa-
rizes the different P2X and P2Y receptors, their functions,
and intracellular signaling pathways in all epithelial tissues.
Relevant information on gut luminal P2 receptors is
summarized in Table 3. Several generalizations can be made
from Table 3. Epithelial cells respond well to ATP and UTP.
P2Y2 and P2Y4 receptors are very prevalent luminal
receptors involved in Cl-, HCO3
-, K+ secretion, or mucin
secretion. Nucleotide stimulation of K+ secretion occurs in
the distal colon, K+ secretion and HCO3
- secretion in the
gallbladder (Table 3; [17, 18, 75, 90]); HCO3
- secretion also
occurs in ducts and is involved in the formation of
pancreatic juice. Stimulation of Cl- secretion occurs in the
gallbladder, small intestine, and duct cells. Ca2+ is the main
second messenger coupled to P2Y receptors, although
cAMP can be involved as well. Region and species
differences occur especially in P2X7 and P2Y6 receptors.
Functional discrimination between P2Y2 and P2Y4 recep-
tors is difficult because of the similar agonist potency
profiles [102]. The persistence of a Cl- secretory response
to UTP or ATP in P2Y2
-/- mice suggested that the response
in mice could be mediated by P2Y4 receptors [32]. Indeed,
loss of nucleotide regulation of epithelial chloride transport
occurs in the jejunum of P2Y4-null mice [90]. P2Y4 mRNA
are expressed in rat and guinea pig submucosa [17, 18, 27],
murine colonic crypts [75], stomach and intestine [90, 105],
and more recently in enteric glial cells [108, 109]. In the
guinea pig small intestine, P2Y4 immunoreactivity is
expressed in enteric glial cells (EGCs) in various regions
of the GI tract except esophagus. EGCs are important
regulators of barrier function, mucosal permeability, neuro-
nal activity, and epithelial cell growth and are active
participants in intestinal inflammation [13, 95]. Some
discrepancy exists between studies on whether P2Y4
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immunoreactivity occurs in epithelial cells, but EGCs may
play a role in the modulation of ion transport in gut
epithelial cells (for review see [95]).
Little evidence exists that luminal P2 receptors activate
absorption, other than the preposition that a P2X7 receptor is
involved in stimulation of Na+/H+ exchanger type 3-
mediated Na+ absorption in rat submandibular gland ducts
[66]. In contrast, data suggest that luminal fluid secretion and
a diarrhea response would occur with activation of luminal
P2Y receptors in small intestine (Cl- secretion) or colon
(inhibition of Na+ absorption via ENaCs and K+ secretion); a
diarrhea response may play a role in host defense reactions
against potential pathogenic invading organisms. Another
possibility is that the P2X7 receptor in villus tip cells that
undergo programmed cell death and exfoliation may act as a
“death signal” to insure villus cell regeneration [43]. The
P2Y6 receptor is a potential therapeutic target in the
treatment of cystic fibrosis gallbladder disease because
UDP retained its ability to promote/stimulate Isc/ion trans-
port changes in cystic fibrosis gallbladder epithelial cells
from CFTR-deficient mice [65].
Basolateral P2Y6 stimulates NaCl secretion
Recent evidence suggests that basolateral P2Y6 receptors
that are sensitive to UDP in colonic epithelia cells stimulate
sustained NaCl secretion by evoking a synergistic increase
in intracellular free Ca2+ and cAMP. In Xenopus oocytes
coexpressing P2Y6 with the cystic fibrosis transmembrane
conductance regulator (CFTR), UDP transiently activated
the Ca2+-activated Cl- current and subsequently CFTR.
A2b receptors in apical secretion
Adenosine is generated at sites of tissue injury or stress
including ischemia, inflammation, and tissue remodeling by
ATP catabolism. Adenosine at inflammatory sites can have
either proinflammatory or anti-inflammatory effects
depending on the receptor or tissue. In crypt abscesses
during periods of active inflammation, ectonucleotidases
convert ATP derived from neutrophils to adenosine.
Adenosine causes vectorial chloride and interleukin-6
secretion [33, 73, 103]. In human jejunum, an A2 receptor
agonist 5′-N-methylcarboxamidoadenosine stimulates
chloride secretion. A2b immunoreactivity is prominent in
human mucosa or epithelial cells of the cecum, colon, and
jejunum (Christofi et al. 1999; [89, 104]).
At rest, in epithelial cells, the A2b receptor is intracellular
and inactive, and agonist stimulation on the apical or
basolateral side of human epithelial cells induces polarized
trafficking and surface expression of the A2b receptor in
intestinal epithelial cells [33]. N-ethylmaleimide attachment
receptor (SNARE) proteins participate in recruitment of
A2b receptors that may be necessary for its signaling. The
A2b receptor signals through the cAMP/protein kinase
A/cAMP response-element binding protein to cause apical
chloride and interleukin-6 secretion. It has been suggested
that interleukin-6 would promote neutrophil degranulation
Table 3 Functional distribution of luminal P2 receptors in GI epithelial cells
Tissue Species P2 receptor Endog. agonist Function Signaling Reference
Jejunum Mouse P2Y4 ATP = UTP Cl
- secretion↑ 32
Duod. villus Rat P2X7 Apoptosis ?? 43
Pancr. duct Guinea pig P2Y2 ATP = UTP HCO3
- secretion↑ Ca2+↑ 52
Rat P2X7 Bz-ATP Ca
2+↑ 47
Rat P2Y2, P2Y4, P2X7 UTP/ATP Cl
- secretion↑ Ca2+↑ 72
Dog ATP Mucin secret. ↑ Ca2+↑ 81
PDEC Human P2Y2/P2Y4 UTP/ATP Cl
- secretion↑ Ca2+↑ 16
CFPAC-1 Mouse P2Y2/P2Y6 ATP = UTP/UDP Cl
- secretion↑ 32
Gallbladder Mouse P2Y2 ATP/UTP HCO3
-secret.↑ Ca2+↑ 23
Necturus P2 ATP Cl-secretion↑ cAMP↑ 107
Bile duct Rat P2Y1, P2Y2 ATP, UTP HCO3
-secret.↑
P2Y4, P2Y6 ADP, UDP
2MeSATP
Rat P2Y2/P2Y4 UTP/ATP Cl
- secretion↑ 96, 100
Colon Rat, mouse P2Y2/P2Y4 UTP/ATP K
+ secretion↑ Ca2+↑ 56
Na+ absorption↓ ?
Caco-2 Human P2Y2, P2Y4, P2Y6 UTP/ATP Cl
- secretion↑ Ca2+↑ 76
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and enhance microbicidal activity of neutrophil trafficking
to the intestinal mucosa [103].
Purinergic regulation of secretion from neuroendocrine
cells in gastric mucosa
A1/gastrin release In the stomach, adenosine protects
against stress-induced gastric ulcer formation by inhibiting
gastric acid secretion by direct action on parietal cells in
some species (guinea pigs and dogs, [42, 48]) but not
others (rats, [86]). A recent study using selective A1 (N6-
cyclopentyladenosine), A2a (CGS 2168), and A3 (IB-
MECA) receptor agonists provided pharmacological proof
that an A1 receptor is negatively coupled to gastrin release
in rat stomach. An A1 receptor selective antagonist 8-
cyclopentyl-1,3-dipropyl-xanthine abolished adenosine
effects on gastrin release, and A1 immunoreactivity was
found on mucosal G cells (gastrin) and D cells (somato-
statin), but not parietal cells (H+ ions, acid). Therefore,
adenosine may suppress gastrin release by activating A1
receptors on G cells, leading to inhibition of gastric acid
secretion [123, 125].
Omeprazole-induced achlorhydria suppresses gene ex-
pression of both A1 and A2a receptors in the antrum and
corpus mucosa. In the vascularly perfused rat stomach,
omeprazole also significantly attenuated the A2a receptor-
mediated stimulation of somatostatin release along with a
corresponding decrease in A2a receptor mRNA expression.
This acid-dependent change in A2a receptor expression is a
regulatory feedback mechanism to control gastric acid
secretion [124]. The A2a receptor agonist ATL-146e could
almost prevent aspirin-induced gastric mucosal lesions [83].
Clinical implications of adenosine deaminase (ADA)
activity Clinical studies suggest that adenosine inhibits
gastric acid secretion and may act as a gastroprotective
agent. For instance, patients suffering from acid hyper-
secretion have higher ADA activity. There is a direct
correlation between ADA activity and gastric acid output in
fundic mucosa of patients with ulcer, gastritis, and
achlorhydria [79]. In patients with gastric ulcers, corpus
mucosa ADA activity is reduced after H2 blocker ranitidine
treatment [80].
A2a receptors and somatostatin release Adenosine admin-
istration to the isolated vascularly perfused rat stomach
inhibits gastrin release and stimulates somatostatin
release [64], a potent inhibitor of gastric acid secretion.
Adenosine analogs augment somatostatin-like immuno-
reactivity release with a potency profile of CGS 21680=
5′-N-ethylcarboxamidoadenosine > 2-chlroadenosine >
R-(-)-N6-(2-phenylisopropyl)adenosine >1-deoxy-1-[6-
[[3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-
β-D-ribofuranuronamide > N6-cyclopentyladenosine =
N6-cyclohexyladenosine > S-(+)-N6-(2-phenylisopropyl)
adenosine, suggesting an A2a receptor involvement. The
A2a receptor antagonist ZM 241385 abolished the CGS
21680 or adenosine stimulation of somatostatin release.
Immunochemical distribution of A2a receptors suggests
that adenosine can act on D cells or indirectly on
myenteric neurons to stimulate somatostatin release and
consequently suppress gastric acid secretion [125].
Gastric preconditioning induced by short ischemia (brief
occlusion of celiac artery for 5 min) protects against
mucosal damage induced by severe ischemia/reperfusion
or topical mucosal irritants in the stomach. Adenosine
release among other mediators [63] contributes to protec-
tion. Adenosine pretreatment (10 mg/kg i.g.) reduced
lesions and improved gastric blood flow similar to ischemic
preconditioning. The adenosine receptor antagonist 8-
phenyltheophiline (10 mg/kg i.g.) attenuated the gastro-
protection due to preconditioning. Furthermore, the selective
A2a receptor agonist ATL-146e (5 μg/kg) attenuated stress-
induced gastric lesions and damage and reduced production
of proinflammatory cytokines [tumor necrosis factor
(TNF)-α, interleukin (IL)-1β] and neutrophil infiltration,
suggesting a protective effect via A2 receptors against ulcer
formation [82].
Reflex-driven intestinal diarrhea and clinical relevance
of purines
The therapeutic potential of purinergic receptors in intesti-
nal secretomotor disorders remains to be established, but
evidence is building in support of endogenous adenosine,
A2a, and A3 receptors as therapeutic targets. Toxin A (TxA)
release from Clostridium difficile (a gram-positive anaero-
bic bacillus) can contribute to antibiotic-induced diarrhea
and pseudomembranous colitis; the latter condition is
associated with significant mucosal secretion and inflam-
mation. The neural circuit mechanism deduced from the
available evidence is shown in Fig. 9. Briefly, activation of
nuclear factor NF-κB initiates a cascade of events involving
epithelial cells, macrophages, neutrophils, mast cells,
extrinsic primary afferent neurons (EPANs), and the ENS
including cholinergic secretomotor neurons. Eventual hy-
perexcitability of neural circuits leads to amplification of
the secretory response and profuse secretion to flush out the
pathogenic organism [25]. The selective A2a receptor
agonist ATL 313 (0.5-5 nM) also reduced Clostridium
difficile TxA-induced secretion and edema, prevented the
mucosal damage and neutrophil infiltration, TxA-induced
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cell death, TNF-α production, as well as increased ileal
ADA activity, in murine ileal loops exposed to TxA. Effects
were reversed by the selective A2a receptor antagonist
ZM241385 (5 nM) [15].
Recent studies provided convincing evidence that activa-
tion of an A2a receptor attenuates intestinal inflammation in
animal models of IBD and may serve as a novel therapy for
IBD [15, 77, 82]. In general, adenosine has diverse
functions in the GI tract in the regulation of secretion,
motility, innate mucosal immunity, is protective against
experimental IBD, and is important in mediating inflamma-
tory responses at sites of injury, and has anti-inflammatory
effects in epithelial cells.
Adenosine is also reported to be a conditionally essential
nutrient for the gut and has been shown to be beneficial in
alleviating severe diarrhea in children with cholera [20,
25, 98].
Recent findings indicate that lumenal adenosine or AMP
can rapidly increase glucose transport by small intestine and
increase systemic availability of 3-O-methyl glucose after an
oral administration to mice. The putative A2 receptor
involved is linked to a signaling pathway involving cAMP
production. Adenosine causes a rapid increase in carrier-
mediated glucose uptake that is suggested to be of clinical
relevance [60]. In contrast to other modulators, adenosine is
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Fig. 9 1 Clostridium difficile toxin A (TxA) stimulates reflex-evoked
intestinal secretion and causes diarrhea. 2 After TxA is internalized in
enterocytes, TxA activates NF-kB and releases LTB4, PGE2, TNF. 3
After NF-kB activation, the proinflammatory mediators interleukins
(IL) are released from monocytes/macrophages (MO). 4 Stimulation of
processes of EPANS occurs, followed by release of substance P (SP)/
CGRP that degranulates mast cells (MC) by activating NK1 receptors.
5 SP-containing EPANS release SP on cholinergic secretomotor
neurons. The mediators released from mast cells include histamine,
5-HT, PGE2, and tryptase. 6 Tryptase acts on PAR2 receptors on
EPANS and on IPANS to stimulate further release of PGE2. 7 The
sympathetic innervation with norepinephrine release and its binding to
α2-adrenergic receptors normally reduces secretion via VIP secreto-
motor neurons. ILs suppress norepinephrine release. These cytokines
act on sympathetics to lift the sympathetic brake exerted by
norepinephrine. TxA-induced release of proinflammatory mediators
degranulates mast cells that amplify neural and secretory responses in
order to maximize secretion in defense of the host. Treatment with an
A2a receptor agonist attenuates the TxA-induced diarrhea presumably
by acting in this reflex pathway. (Modified from [25] by permission)
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supplement in the diet may suggest potential applications in
treatment of malabsorption in chronic intestinal inflamma-
tory diseases. Daily intake of purines is 600-1,000 mg/day
by adult individuals in the USA [99]. It has been estimated
that diet and endogenous adenosine production can con-
tribute 5-6 mM of adenosine in the lumen in individuals on
a Western diet. A concentration of 1 mM luminal adenosine
caused a maximum effect on glucose uptake [60].
In human intestinal epithelial cells, adenosine affects
immune function and exerts anti-inflammatory effects by
acting as a negative regulator of NF-κB and MAPK
signaling. Adenosine pretreatment in HT-29 cells caused a
reduction in stimulated IL-8 expression and secretion [55].
Neurogenic diarrhea
The adenosine A3 receptor is one of the least understood
receptors in secretomotor reflexes. The physiological
relevance of A3 receptor is unclear, and current opinion is
that it may function primarily in disease or abnormal states
such as ischemia/reperfusion injury, tissue damage, gut
inflammation, and extremes in motor activity of the gut
when endogenous adenosine release is sufficiently high to
activate the low affinity receptor [53]. It has been reported
by Cooke et al. [30] that dimaprit–H2R activation of
submucous neurons leads to a stereotypical cyclical pattern
of secretion in coordination with motility that can last for
several hours. The underlying electrophysiological correlate
is cyclical depolarization and excitation of submucous
neurons. This is a model of neurogenic diarrhea involving
an immune-neural circuit. It proved useful in elucidating a
functional role of A3 receptors in addition to A1 receptors in
the secretomotor function and coordination of motility and
secretion [8, 9]. Dimaprit was used to elicit a stereotypical
cyclical increase in short-circuit current (Isc = chloride
secretion) in coordination with motility. Isc was recorded in
guinea pig distal colon simultaneously with muscle length
in the circular orientation by sonomicrometry. A1 receptor-
selective antagonists 8-cyclopentyltheophylline (CPT) or
1,3-dipropyl-8-(2-amino-4-chlorophenyl) xanthine (PACPX)
or the irreversible antagonist FSCPX caused a concentration-
dependent augmentation of coordinated responses; 100 nM
antagonist caused maximum blockade of A1 receptors and
enhanced Isc 133% and ICD 64% with ED50 values in the
nanomolar concentration range. Dimaprit responses were
abolished by 10 nM A1 receptor agonist CCPA and reversed
by A1 receptor antagonists. After knockdown of A1 receptors
with FSCPX (1 μM), the selective A3 receptor agonist
IB-MECA could still abolish coordinated responses (IC50-
Isc=2.1 μM; IC50-ICD=7.1 μM) that could be reversed by
the A3 receptor antagonist MRS1191. The A3 receptor
antagonist alone could also enhance Isc and coordinated
muscle responses. The coordinated response to dimaprit is
abolished by nerve blockade with TTX, and remaining
myogenic activity was reduced by ~50% by IB-MECA after
A1 receptor knockdown with FSCPX. MRS1191 (1 μM)
could enhance TTX-sensitive distension-evoked Isc
responses. A3 receptor immunoreactivity occurs in myenteric
and submucous neurons of guinea pig, mouse, rat, and
human colon (Christofi, unpublished observations). Avail-
ability of knockout models for adenosine receptor subtypes
should provide unequivocal proof of function.
In summary, preliminary data suggest that in a model of
neurogenic diarrhea endogenous adenosine release is
sufficient to act at inhibitory A1 and A3 receptors to
modulate the stereotype neural-motor behavior triggered by
the mast cell mediator histamine. Adenosine A3 receptors
may be targets for modulation of distension-evoked
neurosecretory reflexes as well. The role of A3 receptors
in bowel disorders associated with diarrhea or diarrhea
predominant IBS warrants further investigation.
Differential dysregulation of purinoceptors in GI
disease states
As already described, purinergic signaling regulates all
important physiological functions of the GI tract including
epithelial transport, 5-HT release from EC cells, mucosal
reflexes, sensory signaling in the ENS, synaptic transmis-
sion, as well as coordination of motility and secretion. It is
reasonable then to suggest that these abnormalities in
purinergic receptors or signaling pathways would have a
significant impact on the overall behavior of the gut, enteric
reflexes, and secretomotor behavior of the gut in bowel
diseases. Purinergic receptors in gastrointestinal inflamma-
tion were the subject of a recent review by Kolachala
et al. [61]. A recent study by Guzman et al. [45] using
high-density oligonucleotide microarray analysis and
SYBR-Green RT-PCR validation provided direct proof for
differential dysregulation (upregulation or downregulation
depending on the purine gene) of P2X1, P2X2, P2X4, P2X7,
P2Y1, P2Y2, P2Y4, P2Y6, A2a, A2b, A1, or A3 receptors in
whole thickness gut specimens of experimental trinitroben-
zene sulfonic acid (TNBS) colitis in rats . Expression of A1
and A3 receptor gene products is also altered in a chronic
ileitis model of Crohn’s disease [106]. The ATP-gated ion
channel P2X3 is increased in human IBD [122] as is the
case for TNBS colitis [45]. In submucosal neurons of
TNBS colitis, there is emergence of a purinergic component
of the fast EPSP that is cholinergic in nature in normal
animals [69, 70]. Therefore, there is plasticity of purinergic
neurotransmission. Abnormalities in the neural regulation
of the gastrointestinal vasculature could contribute to the
pathogenesis of IBD. Recent data suggest that reduced
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purinergic neurotransmission via putative P2X1 receptors
may underlie a defect in sympathetic regulation of gut
vasomotor function during TNBS colitis [68]. Changes in
vasomotor function could also impact on secretomotor
responses. Further studies are needed to identify the
location of these receptors in the gut wall and better
understand the functional relevance of these and other
receptor abnormalities on secretomotor and vasomotor
function in various species and in human gut.
It was recently shown that purinergic gene dysregulation
in experimental colitis is sensitive to oral administration of
the A3 receptor agonist IB-MECA, a potential therapeutic
target for IBD [45]. IB-MECA protects against tissue
injury, development of colitis, and prevents dysregulation
of 92% of genes in TNBS colitis, including purine genes.
This illustrates a new important benefit of A3 receptor
agonists in preventing abnormalities in purine gene expres-
sion in colitis. A review by Antonioli et al. [2] discusses the
pharmacological modulation of adenosinergic pathways in
the therapeutic management of IBD. Adenosine A1, A2a,
A2b, and A3 receptors are potential therapeutic targets as
regulators of gut enteric immune responses and all
components of gut motor reflexes [2, 27].
Summary and conclusions
A secretomotor reflex is activated by mucosal stroking,
distension, or chemical stimulation of the mucosa leading to
release of 5-HT or other mediators, subsequent activation of
IPANs in synaptic communication with interneurons or
secretomotor neurons to stimulate chloride and fluid
secretion. Inputs from myenteric neurons modulate secre-
tory rates and reflexes, and special neural circuits exist to
coordinate secretion with motility and vasomotor functions.
All cellular components of secretomotor reflexes express
multiple purinergic receptors for adenosine or the nucleo-
tides ATP, ADP, UTP, or UDP. This review focused on the
emerging concepts in our understanding of purinergic
regulation at these receptors, and in particular of mechano-
sensory reflexes. Endogenous purines can activate inhibi-
tory A1, A3, and P2Y12 receptors or stimulatory A2 and
P2Y1 receptors to modulate 5-HT release. The resting
“secretory tone” is influenced by endogenous purines.
Stimulatory P2Y1 receptor or inhibitory A1/A3 receptors
are involved in mechanically evoked secretomotor reflexes
and a model of neurogenic diarrhea. Recent studies
identified the neural and/or non-neural distribution profiles
of P2X2, P2X3, P2X5, P2Y1, P2Y2, P2Y4, P2Y6, or P2Y12
receptor immunoreactivity in the GI tract suggesting their
role in secretomotor function. Significant species and
regional differences exist in distribution and function of
the receptors. Abnormal expression of purinergic receptors
may contribute to functional abnormalities and diarrhea in
IBD; functional studies are lacking. Adenosine A2a or A3
receptors are emerging as therapeutic targets in IBD and
protect against purinergic receptor abnormalities or profuse
diarrhea. Purines are emerging as fundamental regulators of
enteric secretomotor reflexes in health and disease.
Future studies should be aimed at better understanding
the function of other purinergic receptors expressed in the
enteric nervous system or non-neuronal components of the
reflex, in both rodents and human gut. More integrative
studies on purinergic regulation of chemosensory or
mechanosensory secretomotor reflexes are desperately
needed. This should pave the way to better understand
purine receptor biology, abnormalities in disease states, or
as therapeutic targets.
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